AQUA BIO TECHNOLOGY ASA financials
AQUA BIO TECHNOLOGY ASA
529900RG33DF0N88RJ88 | Line item | 2024 | 2023 |
|---|---|---|
| Income statement | ||
| Revenue | NOK 106.6M | NOK 18.4M |
| Other income | NOK 615.3K | NOK 330.6K |
| Employee benefits expense | NOK 36.4M | NOK 15.7M |
| Raw materials & consumables used | NOK 104.5M | NOK 8.3M |
| Depreciation & amortisation | NOK 11.7M | NOK 3.7M |
| Operating profit (EBIT) | -NOK 325.7M | -NOK 15.8M |
| Net finance income / (cost) | -NOK 19.5M | -NOK 5.1M |
| Finance costs | NOK 20.0M | NOK 5.2M |
| Profit before tax | -NOK 345.2M | -NOK 20.8M |
| Income tax expense | -NOK 7.8M | NOK 178.6K |
| Profit for the year | -NOK 337.4M | -NOK 21.0M |
| Total comprehensive income | -NOK 337.4M | -NOK 21.0M |
| Per share | ||
| Basic EPS | NOK 4.96 | NOK 0.69 |
| Diluted EPS | NOK 4.96 | NOK 0.69 |
| Cash flow statement | ||
| Net cash from operating activities | -NOK 46.9M | -NOK 19.3M |
| Income taxes paid | NOK 98.5K | NOK 0 |
| Net cash from investing activities | NOK 13.0M | -NOK 1.4M |
| Net cash from financing activities | NOK 46.2M | NOK 23.7M |
| Proceeds from borrowings | NOK 24.8M | NOK 10.7M |
| Repayments of borrowings | NOK 9.3M | NOK 0 |
| Lease liability payments | NOK 4.6M | NOK 1.7M |
| Net change in cash | NOK 12.4M | NOK 3.0M |
| Balance sheet | ||
| Total assets | NOK 249.7M | NOK 237.7M |
| Non-current assets | NOK 212.1M | NOK 188.9M |
| Property, plant & equipment | NOK 667.6K | NOK 5.1M |
| Right-of-use assets | NOK 42.6M | NOK 12.0M |
| Intangible assets & goodwill | NOK 75.2M | NOK 123.5M |
| Current assets | NOK 37.6M | NOK 48.8M |
| Inventories | NOK 5.5M | NOK 23.9M |
| Trade & other receivables | NOK 14.4M | NOK 18.2M |
| Cash & equivalents | NOK 17.2M | NOK 4.8M |
| Total equity | -NOK 81.7M | NOK 85.8M |
| Non-current liabilities | NOK 132.7M | NOK 32.5M |
| Long-term borrowings | NOK 52.7M | NOK 9.3M |
| Lease liabilities (non-current) | NOK 48.3M | NOK 14.9M |
| Current liabilities | NOK 198.7M | NOK 119.5M |
| Short-term borrowings | NOK 92.2M | NOK 22.8M |
| Lease liabilities (current) | NOK 12.1M | NOK 5.6M |
| Trade & other payables | NOK 87.9M | NOK 67.1M |
| Deferred tax liabilities | NOK 18.5M | NOK 7.4M |
| Derived metrics | ||
| Free cash flow | -NOK 47.9M | -NOK 19.3M |
| Operating margin | -305.7% | -85.8% |
| Net margin | -316.6% | -114.2% |
| Return on equity | 412.7% | -24.5% |
| Cash conversion ratio | 0.14× | 0.92× |
| Capex coverage | -43.51× | -282.62× |
| Other reported items | ||
| Additional Paidin Capital | NOK 10.6M | NOK 6.2M |
| Adjustments For Decrease Increase In Inventories | NOK 41.1M | NOK 1.1M |
| Adjustments For Decrease Increase In Trade and Other Receivables | NOK 60.7M | -NOK 322.0K |
| Adjustments For Depreciation and Amortisation Expense | NOK 11.7M | NOK 3.7M |
| Adjustments For Finance Costs | NOK 19.5M | NOK 5.1M |
| Adjustments For Impairment Loss Reversal of Impairment Loss Recognised In Profit Or Loss | NOK 163.7M | NOK 798.6K |
| Adjustments For Increase Decrease In Other Liabilities | -NOK 12.4M | -NOK 67.9K |
| Adjustments For Increase Decrease In Trade Account Payable | -NOK 24.7M | NOK 3.4M |
| Adjustments For Sharebased Payments | -NOK 608.6K | NOK 2.2M |
| Cash Flows Used In Obtaining Control of Subsidiaries Or Other Businesses Classified As Investing Activities | -NOK 14.0M | -NOK 496.4K |
| Current Finance Lease Receivables | NOK 438.5K | NOK 1.8M |
| Current Investments | NOK 0 | NOK 178.6K |
| Current Provisions | NOK 5.0M | NOK 24.0M |
| Current Tax Liabilities Current | NOK 1.6M | NOK 0 |
| Deferred Tax Assets | NOK 0 | NOK 0 |
| Effect of Exchange Rate Changes On Cash and Cash Equivalents | NOK 0 | NOK 0 |
| Equity and Liabilities | NOK 249.7M | NOK 237.7M |
| Finance Income | NOK 575.6K | NOK 115.7K |
| Impairment Loss Reversal of Impairment Loss Recognised In Profit Or Loss | NOK 163.7M | NOK 798.6K |
| Increase Decrease In Contingent Consideration Asset Liability | -NOK 5.0M | — |
| Increase Decrease Through Exercise of Options | -NOK 608.6K | NOK 2.3M |
| Interest Paid Classified As Financing Activities | NOK 3.1M | NOK 484.1K |
| Interest Received Classified As Operating Activities | NOK 301.7K | NOK 2.6K |
| Issue of Equity | NOK 165.4M | NOK 102.6M |
| Liabilities | NOK 331.4M | NOK 152.0M |
| Noncurrent Finance Lease Receivables | NOK 70.3K | NOK 6.4M |
| Noncurrent Provisions | NOK 13.3M | NOK 853.1K |
| Other Comprehensive Income | -NOK 218 | NOK 10.9K |
| Other Comprehensive Income Net of Tax Exchange Differences On Translation | -NOK 218 | NOK 10.9K |
| Other Inflows Outflows of Cash Classified As Investing Activities | NOK 0 | -NOK 490.8K |
| Other Intangible Assets | NOK 92.2M | NOK 41.1M |
| Other Noncurrent Receivables | NOK 1.4M | NOK 761.8K |
| Payments For Development Project Expenditure | NOK 0 | NOK 1.3M |
| Proceeds From Issuing Shares | NOK 37.6M | NOK 14.8M |
| Purchase of Property Plant and Equipment Intangible Assets Other Than Goodwill Investment Property and Other Noncurrent Assets | NOK 1.1M | NOK 68.2K |
| Retained Earnings | -NOK 412.0M | -NOK 74.7M |
| Revenue and Operating Income | NOK 107.2M | NOK 18.7M |
| Selling General and Administrative Expense | NOK 77.3M | NOK 20.3M |
| Share Premium | NOK 47.6M | NOK 14.3M |
| Treasury Shares | NOK 31.9K | NOK 31.9K |
Every line item above is a fact tagged in AQUA BIO TECHNOLOGY ASA's annual report
filed in the European Single Electronic Format (ESEF) under the IFRS
taxonomy (ifrs-full) — the income statement, balance sheet
and cash-flow statement as the filer reported them. Values are shown
as-is, in the reporting currency (NOK), without
rescaling; the row labels map to the underlying concept name (e.g.
Revenue → ifrs-full:Revenue, Operating profit →
ifrs-full:ProfitLossFromOperatingActivities, Diluted EPS →
ifrs-full:DilutedEarningsLossPerShare), and any concept
without a curated label is shown under “Other reported items” with its
de-camel-cased tag name. Only consolidated, default-member facts are
shown (segment / dimensional breakdowns are excluded).
“Derived metrics” (free cash flow, margins, ROE, …) are computed from those facts by the same model the U.S. financials pages use — not tagged by the filer.
Source: machine-readable OIM xBRL-JSON aggregated by filings.xbrl.org (XBRL International). Entity identity is resolved by LEI via the public-domain GLEIF register. This is reference data, not investment advice.